An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus
Latest Information Update: 15 Jan 2024
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational
- Sponsors Cara Therapeutics
Most Recent Events
- 09 Jan 2024 Results assessing the impact of intravenous difelikefalin on HRQoL in haemodialysis patients with moderate-to-severe CKD-aP, published in The Patient - Patient-Centered Outcomes Research
- 15 Nov 2023 Results of pooled dataset from KALM-1 and KALM-2 and NCT03998163 , evaluating whether itch reduction in CKD-aP improved sleep quality, published in the Nephrology Dialysis Transplantation
- 21 May 2020 Status changed from active, no longer recruiting to completed.